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Abstract
Schizophrenia is a debilitating disease that affects approximately 21 million people
worldwide (APA, 2013). The gold standard of treatment of schizophrenia is antipsychotic
medications. Unfortunately, approximately 50% of patients become non-compliant with their
prescribed medications (Sadock, Sadock & Ruiz, 2015). The purpose of this DNP project was to
determine the effect of implementing an education intervention regarding long acting injectable
(LAI) antipsychotics on the knowledge of advanced practice providers working at a state
psychiatric hospital. The advanced practice providers that participated in this DNP project
completed a pre-education assessment, attended a brief educational session regarding LAI
antipsychotics, and completed a post-education assessment two weeks later. Though the results
were limited by the number of participants, it was found that after implementing an educational
session regarding LAI antipsychotics advanced practice providers had improved knowledge
about and self-efficacy in prescribing of LAI antipsychotics, and reported a greater willingness to
prescribe LAI antipsychotics in the future.
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Background and Significance
Problem Identification
Schizophrenia is a debilitating disease characterized by cognitive, behavioral and
emotional dysfunctions that cause significant impaired occupational or social functioning. It
typically presents with delusions, hallucinations and disorganized speech (APA, 2013). The
overall lifetime prevalence of schizophrenia is approximately 0.7% among populations
worldwide (APA, 2013) and more than 23 million people worldwide are affected by this disease
(WHO, 2019). Schizophrenia is more common and typically presents earlier among males, but
both males and females are affected by this chronic disease (WHO, 2019).
Context of the Problem
There is a two to three percent greater than expected early mortality rate among those
with schizophrenia than the general population (WHO, 2019). Having a mental illness like
schizophrenia is a barrier to appropriate medical care and is associated with medical morbidity
and mortality (Gur et al., 2018). This is largely attributed to comorbid medical problems such as
cardiovascular disease, metabolic disease and infections (WHO, 2018). Unfortunately, suicide is
also a large contributing factor to mortality among those diagnosed with schizophrenia; nealy
20% of this population attempt and about 5%-6% die as a result of suicide (APA, 2013).
Medication nonadherence is also associated with a greater risk for suicide and medical morbidity
and mortality among people with schizophrenia (El-Mallakh & Findlay, 2015). Despite first-line
antipsychotic medications being effective in approximately 70%-80% of this population, an
estimated that 50% become nonadherent to their medication regimen (El-Mallakh & Findlay,
2015).
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Scope and Consequences of the Problem
Antipsychotic medications are the gold standard for schizophrenia treatment and consist
of older first-generation antipsychotics and newer second-generation antipsychotics (Sadock,
Sadock & Ruiz, 2015). Unfortunately, oral antipsychotic medication nonadherence is a frequent
problem and is the most common cause of a psychotic relapse (Kaplan, Casoy & Zummo, 2013).
The Clinical Antipsychotic Trials of Intervention Effectiveness study report that 74% of those
diagnosed with schizophrenia become nonadherent with their antipsychotic medication within 18
months of the medication being prescribed (Higashi et al., 2013). Approximately 53% to 72%
percent of those who are nonadherent with antipsychotic medications experience a psychotic
relapse (Sadock, Sadock & Ruiz, 2015). However, Long Acting Injectable (LAI) antipsychotics
are an alternative to traditional oral and older depot antipsychotics (Kaplan, Casoy & Zummo,
2013). LAIs are also associated with improved medication compliance and improved patient
outcomes (Kaplan, Casoy & Zummo, 2013).
Evidenced Based Intervention
Provider education has been demonstrated to be an effective evidence-based intervention
in improving knowledge about schizophrenia and its treatment (Turrina et al., 2008). LAI
antipsychotics have been shown to increase the success of schizophrenia treatment by improving
medication adherence, maintaining more consistent medication bioavailability, lowering
symptom relapse rates, and improving patient outcomes (Brissos, Veguilla, Taylor, BalanzaMartinez, 2014). In comparison to oral antipsychotics, LAIs have also been associated with
decreased number of ER visits, decreased lengths of hospital stays, and decreased rates of rehospitalization among those with schizophrenia (Lafeuille et al., 2013). Provider education on
LAI antipsychotics can also be a relatively inexpensive intervention to improve the care of those

2

THE EFFECT OF LAI PSCHOTROPIC MEDICATION
diagnosed with schizophrenia. The average cost per learner in continuing medical education is as
low as $37 (Sullivan, 2018).
When searching for educational opportunities regarding LAI antipsychotics a variety of
published research papers and recommendations from health networks can be found, but no
educational programs regarding LAI antipsychotics are currently available. The
Psychopharmacology Institute (2018) has a published guide entitled “Long-Acting Injectable
Antipsychotics: A Summary for Prescribers” which summarizes the most clinically relevant
information regarding the use of LAI antipsychotics (Guzman, 2018). This guide is a four-page
document written by Dr. Flavio Guzman, who is a psychiatrist and assistant professor of
pharmacology at the University of Mendoza (Psychopharmacology Institute, 2018). This
resource was intended to be used as a guide to reference the most clinically relevant features and
prescribing facts of LAI antipsychotics (Guzman, 2018). For this DNP project the guide is used
as the content for an educational session delivered to advanced practice providers. It was further
chosen because it clearly presents who should receive LAI antipsychotics, the practical
considerations of prescribing LAI antipsychotics, and the potential advantages and disadvantages
of LAI antipsychotics (Guzman, 2018).
Purpose of the Project
The purpose of this project was to determine the effect of implementing an education
intervention regarding LAI antipsychotics on the knowledge of advanced practice providers. The
project aims were to identify barriers to prescribing LAI antipsychotics among advanced practice
providers; assess the effect of implementing education regarding LAI antipsychotics on
providers comfort in prescribing LAI antipsychotics; and examine the effect of implementing
education regarding LAI antipsychotics on providers likelihood to prescribe LAI antipsychotics.
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Theoretical Model
The theoretical model that guided this DNP project was the Diffusion of Innovation
Theory, which focuses on the dissemination of new information (Zhang, Yu, Yan, & Spil, 2015).
The Diffusion of Innovation Theory categorizes an innovation into one of five possible qualities
including the relative advantage, compatibility, complexity, trialability and observability of the
innovation. If the innovation is perceived by others as beneficial, it will likely be adopted
(Zhang, Yu, Yan, & Spil, 2015). This theory also states that the spread of innovation is a process
by which people adopt new ideas, practices, and philosophies. When a new idea is developed, a
limited number of people are initially open to the idea. With time, however, the new idea spreads
to more people and may become accepted by most. The theory categorizes people into one of
five categories (innovators, early adopters, early majority, late majority, and laggards) based on
the state in which a person adopts an innovation (Kaminski, 2011).
When implementing an educational session on LAI antipsychotics, it was important to
present the information of LAI antipsychotics as beneficial. It was also important to understand
the characteristics of the advanced practice providers who would participate in the educational
session. Based on the Diffusion of Innovation Theory, most advanced practice providers fall into
the early majority category because they want proven applications that have reliable results. This
includes utilizing prescribing practices that come with appropriate references. Considering these
characteristics, it was likely that the advanced practice providers would perceive LAI
antipsychotic education as a beneficial endeavor.
Review of Literature
LAI antipsychotics are an effective alternative approach to oral antipsychotics and can
improve medication adherence to antipsychotic medication (Kaplan, Casoy & Zummo, 2013).
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Greene et al. (2018) reported that medication adherence and discontinuation were examined
between two separate groups of patients that received LAI antipsychotics versus oral
antipsychotics. Those who received LAI antipsychotics were more adherent and 20% less likely
to discontinue their antipsychotic medication (Green et al., 2018). Adherence to antipsychotic
medications is important because it is the leading preventative measure of symptom relapse
among those with schizophrenia (Kaplan, Casoy & Zummon, 2013). LAI antipsychotics have
shown to prevent symptom relapse. A systematic review by Zhornitsky and Strip (2012)
indicated that psychotic relapse is lower with LAI antipsychotics versus oral antipsychotics.
Further evidence-based support for the use of LAI antipsychotics can be found in The Electronic
Schizophrenia Treatment Adherence Registry, an international long-term study of schizophrenia
patients that are started on new treatment. A study from the registry data showed that after 12
months of switching from an oral to an LAI antipsychotic the percentage of patients that relapsed
was considerably lower for those who received LAI antipsychotics versus those who took oral
antipsychotics (14.6% vs 52.2%) (Olivares, Rodriquez-Martinez, Buron, Alonso-Escolano,
Rodriguez, 2008). Rates of hospitalization and lengths of stay are also noted to be lower among
those treated with LAI versus oral antipsychotics (Lafeuille et al., 2013). A systematic review by
Park et al. (2018) found strong evidence that LAI antipsychotics have higher efficacy at treating
schizophrenia. In the review, those treated with LAI antipsychotics had lower rates of relapse
and shorter hospital stays as compared to those on oral antipsychotics (Park et al., 2018). Peng et
al. (2011) found that after starting LAI antipsychotics, hospital rates among those with
schizophrenia declined from 49.7% to 22.4 % and lengths of hospital stay declined from 7.3 to
4.7 days.
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Educational outreach visits can be effective in improving knowledge and changing
practice among health care providers (O’brien et al., 2007). Educational outreach visits are faceto-face educational sessions in which trained individuals visit healthcare providers where they
practice and provide education about their practice (O’Brien et al., 2007). This type of visit can
be more effective than no educational intervention or other types of education such as
distribution of educational materials (Grimshaw, 2004). Prescribing practices have specifically
been influenced by educational outreach visits in several research studies (Freemantle et al.,
2003; Fretheim et al., 2006; Soumerai, Salem-Schatz, & Avorn, 1999; Witt, Knudsen, Ditlevsen,
& Hollnagel, 2004). For example, a randomized control trial which evaluated the effectiveness of
educational outreach visits on prescribing practices among 162 healthcare providers in 69
practices found that smaller practices had substantial reactions to educational outreach visits
(Freemante et al., 2003). Smaller practices improved in prescribing according to practice
guidelines by 13.5%, versus larger practices that only improved by 1.4% (Freemante et al.,
2003). Freemante et al. (2003) also found that no specific guideline proved more or less
effective than other guidelines, rather, small practice size was most consistent with improved
prescribing patterns.
A thorough review of the literature did not result in research pertaining to specific
education of providers specifically about LAI antipsychotics. However, a review of the literature
supports the notion that education sessions cane improve provider knowledge regarding
medications and prescribing practices on a variety of medications (Freemante et al., 2003,
Avourn & Soumerai, 1983, Diwan et al., 1995).
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Agency Description
Setting
The DNP project was implemented at Eastern State Hospital (ESH) in Lexington,
Kentucky. ESH is a state psychiatric hospital in Lexington, KY, that provides care to residents
from the rural 50 counties of the eastern region of Kentucky. Up to 196 patients can be receive
care at a given time by approximately 15 providers, which consists of psychiatrists, nurse
practitioners and physician assistants (ESH, n.d.).
Target Population
Advanced practice providers, which included psychiatric mental health nurse
practitioners and physician assistants, were the target population for this project. The inclusion
criteria were board certified advanced practice providers (Psychiatric Mental Health Nurse
Practitioners or Physician Assistants) who provided care to patients on an inpatient care unit at
ESH. Exclusion criteria were advanced practice providers that worked solely in the admissions
unit because LAI antipsychotics are not regularly prescribed by providers in the admissions unit.
It was anticipated that the sample size would consist of 10 advanced practice providers; however,
only four advanced practice providers participated in the educational intervention. The sample
consisted of two psychiatric mental health nurse practitioners and two physician assistants.
Congruence of DNP Project and ESH
The mission of ESH is to instill hope, inspire recovery and improve the overall wellbeing
of Kentuckians through providing excellent mental healthcare (ESH, n.d.). This mission is
achieved through their values that include diversity, innovation, respect, compassion and
teamwork (ESH, n.d.). The purpose of this DNP project was to improve the knowledge of
advanced practice providers by implementing an educational session regarding LAI
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antipsychotics. This project contributed to ESH’s mission by improving advanced practice
providers knowledge of long acting injectable antipsychotics which will likely improve the
wellbeing of many Kentuckians with mental illness.
Description of Stakeholders
The stakeholders of this project included the advanced practice providers, the chief
medical officer and the chief nursing officer at ESH. Improvement in advanced practice provider
knowledge regarding long acting injectable antipsychotics is likely most important to the key
stakeholders, which are those diagnosed with schizophrenia.
Site-Specific Facilitators and Barriers
There were several people that facilitated the implementation of this project at ESH. Both
the chief nursing officer and chief medical officer supported and approved this project. The chief
medical officer was helpful in communicating between the primary investigator and the
advanced practice providers, and allowed for the advanced practice providers to have time to
complete the project during their regularly scheduled working hours. The assistant to the chief
medical officer was also helpful in scheduling a designated room for the primary investigator to
meet with the advanced practice providers. The only identified barrier was that some advanced
practice providers were not able to participate in the project due to competing work obligations,
such as patient needs, during the time of the educational sessions.
Project Design
A pre and posttest design was used to examine advanced practice provider’s knowledge
and level of comfort prescribing long acting injectable antipsychotics. An existing assessment
tool to assess provider knowledge regarding LAI antipsychotics was unable to be found in the
literature, so a pre and post education assessment tool was developed by the primary investigator.
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Face validity of the assessment tools were established by having expert psychiatric mental health
nurse practitioners review and recommend edits to the assessment tools. The pre-education
assessment tool (shown in Appendix A) examined the advanced practice providers’ knowledge
regarding the advantages, frequency of side effects and appropriate prescribing of LAI
antipsychotics. It also assessed for qualitative data asking the advanced practice providers what
they perceived as the largest barriers to prescribing LAI antipsychotics and if they were
comfortable prescribing LAI antipsychotics. The post-education assessment tool (shown in
Appendix B) again assessed the advanced practice providers’ knowledge regarding the
advantages, frequency of side effects and appropriate prescribing of LAI antipsychotics. The
post-education assessment tool also asked if the advanced practice providers felt more
comfortable prescribing LAI antipsychotics and if they thought they would prescribe LAI
antipsychotics more often after receiving education about LAI antipsychotics. No demographic
data on the advanced practice providers was collected because collecting such data with a small
sample size would reduce anonymity.
Project Methods
Procedure
An expedited medical IRB application was submitted to and approved by the University
of Kentucky Institutional Review Board. Advanced practice providers who were providing who
met eligibility criteria at ESH were invited via email on January 18, 2019, to take part in the
project. A message from the primary investigator was emailed by the ESH medical director, via
departmental email, inviting the advanced practice providers to participate in the study. This
message was the initial contact of the primary investigator with the advanced practice providers
regarding this project. The email message described the study, requested the advanced practice
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providers participation in the study, and included an informed consent form. The advanced
practice providers that volunteered to be in the study met with the primary investigator at ESH to
complete the informed consent, to complete a 20-minute pre-education written assessment, and
to attend a brief educational session on January 24, 2019. The advanced practice providers were
then given a paper copy of the educational material by the Psychopharmacology Institute to
review during their own time. The primary investigator met with the advanced practice providers
at ESH two weeks later, on February 7, 2019, for a post education 20-minute written assessment.
Results
Pre and post education assessment results were compared to determine if there was a
response to the educational intervention. No inferential analyses were completed because the
small sample size. The pre-education assessment results showed that 75% of the participants
were quite knowledgeable about most aspects of LAI antipsychotics. Every participant correctly
answered the questions regarding LAI antipsychotics effects on risk of rehospitalization and the
potential advantages of LAI antipsychotics. Results from the pre-education assessment also
showed that every participant correctly answered which LAI antipsychotic requires a two-week
bridge therapy with an oral antipsychotic. However, 75 % of the participants incorrectly
responded to what should be done with an oral antipsychotic after the patient has a therapeutic
level of a LAI antipsychotic. One participant answered 100% of the eight knowledge-based
questions correctly, one participant answered 87.5% of the eight knowledge-based questions
correctly, and one participant answered 75% of the eight knowledge-based questions correctly.
Though most of the participants answered a majority of the questions correctly, one of the
participants answered 50% of the knowledge-based questions incorrectly.

10

THE EFFECT OF LAI PSCHOTROPIC MEDICATION
Post-education assessment results revealed improved knowledge regarding LAI
antipsychotics among the participants. Knowledge among the participants regarding what to do
with an oral antipsychotic after a patient has a therapeutic level of a LAI antipsychotic improved
from the pre-education assessment to the post education assessment (25% to 75%). Knowledge
regarding who should receive LAI antipsychotics, side effects, and plasma concentrations all
improved to 100% of the participants answering those questions correctly. However, the
percentage of participants that correctly answered which LAI antipsychotic require a two-week
bridge therapy dropped from 100% to 75%. The same participant that correctly answered 100%
of the pre-education assessment questions, again answered 100% of the post education questions
correctly. The participant that answered 87.5% of the pre-education assessment questions
correctly again correctly answered 87.5% of the post education assessment questions. The
participant that answered 75% of the pre-education assessment questions correctly answered
100% of the post-education assessment questions correctly. The participant that answered 50%
of the pre-education assessment questions correctly answered 87.5% of the post-education
assessment questions correctly. The percentages of correct response among the group of
participants is shown in Table 1.
The pre-education assessment also asked the participants what they perceived to be the
largest barriers to prescribing LAI antipsychotics. A common theme was mentioned by three of
the participants. They wrote that the difficulty associated with finding a place for patients to
receiving LAI antipsychotic injections after being discharged from the hospital was a
considerable barrier to prescribing LAI antipsychotics. One of the participants also mentioned
that cost was a barrier. Both the pre and post education assessments asked the participants to rate
their comfort level of prescribing LAI antipsychotics on a Likert scale. Three of the four
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participants strongly agreed that they were comfortable prescribing LAIs prior to the education
session. All of the participants strongly agreed after the education session. Each of the
participants also strongly agreed that after the educations sessions they would prescribe LAI
antipsychotics more often.
Discussion
The findings of this DNP project support the notion that implementing an educational
session regarding LAI antipsychotics can improve the knowledge of advanced practice providers.
The results also showed that educational sessions can improve advanced practice providers
comfort level in prescribing LAI antipsychotics. Improving advanced practice providers
knowledge and comfort levels of prescribing LAI antipsychotics may explain why the advanced
practice providers believed they would prescribe LAI antipsychotics more often.
The results of this DNP project were similar to the results of prior research that
implementing provider education can improve provider knowledge and comfort level (Dacey et
al., 2012; Drexel et al, 2011); this is the first time that there has been an analysis to determine the
effect of implementing an education intervention specific to APPs regarding LAI antipsychotics.
This is important because of the number of APPs that are providing care to patients is rapidly
growing (Auerbach, Staiger & Buerhaus, 2018). This is also important because of the impact that
LAI antipsychotics can have in the treatment of those with schizophrenia.
The Psychopharmacology Institutes “Long-Acting Injectable Antipsychotics: A
Summary for Prescribers” (Guzman, 2018) guide was of value to use for this project because it
contains information that is of value to APPs. It contains the most relevant information of LAI
antipsychotics including information regarding who should receive LAI antipsychotics, key
prescribing facts, and the potential advantages and disadvantages of LAI antipsychotics. It is
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unknown if the guide has been used as the content of an educational session in prior studies, but
the guides succinct format allowed for the educational session of this DNP project to be brief and
focused on the information that is most applicable to APPs practice. Though the guide is
valuable, it only gives the typical dosing of the older first-generation LAI antipsychotics, and
does not include their practical considerations.
APPs working in the hospital setting are fortunate to work with staff, such as registered
nurses, who can administer LAI antipsychotics. In the community setting, however,
administering LAI antipsychotics can be difficult due to the lack of needed staff to ensure
injections are given. The APPs in this DNP project perceived that the difficulty associated with
continuing LAI antipsychotics after a patient is discharged from the hospital was a barrier to
prescribing LAI antipsychotics. While several states have not permitted pharmacists to
administer LAI antipsychotics, Kentuckians are fortunate that pharmacists are allowed to
administer LAI antipsychotic injections. (Smart Retailing Rx, 2018). As the number of
pharmacists allowed to administer non-vaccine injections increases across the country, patients
will have improved access to LAI antipsychotics in the community setting. In addition to
increased access to LAI antipsychotic injections in the community, many patients report higher
satisfaction with receiving LAI antipsychotics from community pharmacists compared to
alternative settings (Mooney et al., 2018).
The findings of this DNP project support that APPs knowledge regarding LAIs can
improve after participating in an educational session, however if the project were to be
conducted again it would be valuable to differentiate the scores of psychiatric mental health
nurse practitioners and physician assistants. This would provide insight into which group of
APPs benefit from educational sessions. It would also be beneficial to ask the participants what
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they thought of the educational session so that future educational sessions could be tailored to
APPs preferences.
Implications
This DNP project demonstrates that implementing educational sessions can improve
knowledge among advance practice providers. Utilizing existing resources, like “Long-Acting
Injectable Antipsychotics: A Summary for Prescribers” by the Psychopharmacology Institute
(Guzman, 2018), is only one example of how to provide current resources to improve the
knowledge of advanced practice providers. A possible implication related to this DNP project
would be the development of educational sessions specifically designed for advanced practice
providers that are currently practicing. Many advanced practice providers hold an important role
in the treatment of those with schizophrenia and education regarding LAI antipsychotics would
likely improve the outcomes of those with schizophrenia.
Limitations
A limitation of this DNP project included the small number of participants who met the
inclusion criteria and agreed to participate. Only four out of the seven available advanced
practice providers at ESH agreed to participate. Another limitation was the incomplete response
by one of the participants when completing their pre-education assessment. This participant did
not answer what they perceived as the largest barriers to prescribing LAI antipsychotics.
Conclusion
Schizophrenia can be a difficult disorder to treat with as many as 74% of patients with
schizophrenia becoming nonadherent with medications (Higashi et al., 2013). LAI antipsychotics
are an effective alternative to traditional oral and older depot medications that have been shown
to improve medication adherence and reduce relapse of patients’ psychotic symptoms (Green et
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al., 2018). The importance of educating providers about LAI antipsychotics was supported by the
results of this DNP project, but future studies should include later follow up to determine if
improved knowledge can be sustained. Future studies should also evaluate if improved provider
knowledge regarding LAI antipsychotics results in changes in provider prescribing behavior and
improved patient outcomes.
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Appendix A
Pre-Education
Long Acting Injectable (LAI) Antipsychotic Questionnaire
1. LAI’s provide a better relationship between dose and blood levels because:
a. LAI’s avoid first pass metabolism
b. LAI’s provide higher and more frequent peak plasma levels
c. LAIs require bridge therapy
d. All LAI’s are administered q 2 weeks
2. Plasma concentrations are:
a. More stable with LAI’s compared to orally administered antipsychotics
b. More stable with orally administered antipsychotics compared to LAI’s
c. Equal regardless of antipsychotic administration route
3. Side effects are:
a. Less common with orally administered antipsychotics
b. Less common with LAIs
c. Equally common among LAI’s and orally administered antipsychotics
4. Risk of re hospitalization is:
a. Less common with LAI’s
b. Less common with orally administered antipsychotics
c. Equally common among LAI’s and orally administered antipsychotics
5. Which LAI requires a 2-week bridge therapy?
a. Risperdal Consta requires 2-week bridge with oral Risperidone
b. Invega Sustenna requires 2-week bridge with oral Paliperidone
c. Abilify Mantenna requires 2-week bridge therapy with oral Aripiprazole
d. Invega Trinza requires 2-week bridge therapy with oral Paliperidone
6. After the patient has a therapeutic level of the LAI, what would you recommend for the
PO agent?
a. Stop the oral medication
b. Taper the oral medication
c. Continue the oral medication along with the LAI
7. Who should receive LAI’s?
a. Only those who have not responded to 2 or more orally administered
antipsychotics
b. Those with recent onset psychosis
c. Those with risk factors for medication noncompliance
d. B & C
8. What are potential advantages of LAI’s? (choose all that apply)
a. LAI’s reduce the risks of accidental or deliberate overdose
b. LAIs require slow dose titration
c. LAI’s provide a mechanism for monitoring medication compliance
d. A&C
16
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9. What do you perceive as the largest barriers to prescribing LAI’s?

1.
2.
3. Neither
Strongly Disagree Agree or
Disagree
Disagree
10. Are you currently comfortable
prescribing LAIs?
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4.
Agree

5.
Strongly
Agree

THE EFFECT OF LAI PSCHOTROPIC MEDICATION
Appendix B
Post-Education
Long Acting Injectable (LAI) Antipsychotic Questionnaire
10. LAI’s provide a better relationship between dose and blood levels because:
a. LAI’s avoid first pass metabolism
b. LAI’s provide higher and more frequent peak plasma levels
c. LAIs require bridge therapy
d. All LAI’s are administered q 2 weeks
11. Plasma concentrations are:
a. More stable with LAI’s compared to orally administered antipsychotics
b. More stable with orally administered antipsychotics compared to LAI’s
c. Equal regardless of antipsychotic administration route
12. Side effects are:
a. Less common with orally administered antipsychotics
b. Less common with LAIs
c. Equally common among LAI’s and orally administered antipsychotics
13. Risk of re hospitalization is:
a. Less common with LAI’s
b. Less common with orally administered antipsychotics
c. Equally common among LAI’s and orally administered antipsychotics
14. Which LAI requires a 2-week bridge therapy?
a. Risperdal Consta requires 2-week bridge with oral Risperidone
b. Invega Sustenna requires 2-week bridge with oral Paliperidone
c. Abilify Mantenna requires 2-week bridge therapy with oral Aripiprazole
d. Invega Trinza requires 2-week bridge therapy with oral Paliperidone
15. After the patient has a therapeutic level of the LAI, what would you recommend for the
PO agent?
a. Stop the oral medication
b. Taper the oral medication
c. Continue the oral medication along with the LAI
16. Who should receive LAI’s?
a. Only those who have not responded to 2 or more orally administered
antipsychotics
b. Those with recent onset psychosis
c. Those with risk factors for medication noncompliance
d. B & C
17. What are potential advantages of LAI’s? (choose all that apply)
a. LAI’s reduce the risks of accidental or deliberate overdose
b. LAIs require slow dose titration
c. LAI’s provide a mechanism for monitoring medication compliance
d. A&C
18
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18. What have you learned from the LAI education that might change your practice?

1.
2.
3. Neither
Strongly Disagree Agree or
Disagree
Disagree
10. After the education you received
about LAIs are you more comfortable
prescribing LAIs?
11. After the education you received
do you think you will prescribe LAIs
more often?

19

4.
Agree

5.
Strongly
Agree
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Table 1. Pre and Post Assessment Results

1. LAI’s provide a better
relationship between
dose and blood levels
because:
a. LAI’s avoid first
pass metabolism
b. LAI’s provide
higher and more
frequent peak
plasma levels
c. LAIs require
bridge therapy
d. All LAI’s are
administered q 2
weeks
2. Plasma concentrations
are:
a. More stable with
LAI’s compared to
orally
administered
antipsychotics
b. More stable with
orally
administered
antipsychotics
compared to LAI’s
c. Equal regardless
of antipsychotic
administration
route
3. Side effects are:
a. Less common with
orally
administered
antipsychotics
b. Less common
with LAIs
c. Equally common
among LAI’s and

Pre-education
% correct
75%

Post-education
%correct
100%

75%

100%

75%

100%
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orally
administered
antipsychotics
4. Risk of re hospitalization
is:
a. Less common
with LAI’s
b. Less common with
orally
administered
antipsychotics
c. Equally common
among LAI’s and
orally
administered
antipsychotics
5. Which LAI requires a 2week bridge therapy?
a. Risperdal Consta
requires 2-week
bridge with oral
Risperidone
b. Invega Sustenna
requires 2-week
bridge with oral
Paliperidone
c. Abilify Mantenna
requires 2-week
bridge therapy
with oral
Aripiprazole
d. Invega Trinza
requires 2-week
bridge therapy
with oral
Paliperidone
6. After the patient has a
therapeutic level of the
LAI, what would you
recommend for the PO
agent?
a. Stop the oral
medication

100%

100%

100%

75%

25%

75%
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b. Taper the oral
medication
c. Continue the oral
medication along
with the LAI
7. Who should receive
LAI’s?
a. Only those who
have not
responded to 2 or
more orally
administered
antipsychotics
b. Those with recent
onset psychosis
c. Those with risk
factors for
medication
noncompliance
d. B & C
8. What are potential
advantages of LAI’s?
a. LAI’s reduce the
risks of accidental
or deliberate
overdose
b. LAIs require slow
dose titration
c. LAI’s provide a
mechanism for
monitoring
medication
compliance
d. A&C

75%

100%

100%

100%

22

THE EFFECT OF LAI PSCHOTROPIC MEDICATION
References
Auerbach, D., Staiger, D., & Buerhaus, P. (2018). Growing Ranks of Advanced Practice
Clinicians — Implications for the Physician Workforce. The New England Journal of
Medicine, 378(25), 2358-2360.

Brissos, S., Veguilla, M.R., Taylor, D., & Balanza-Martinez, V. (2014). The role of long acting
injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic advances in
Psychopharmacology, 2045125314540297
Dacey, M., Arnestein, F., Kennedy, M., Wolfe, J., & Phillips, E. (2013). The impact of lifestyle
medicine continuing education on provider knowledge, attitudes, and counseling behaviors.
Medical Teacher, 35(5), 1149-1156
Diwan, Wahlström, Tomson, Beermann, Sterky, & Eriksson. (1995). Effects of "group detailing"
on the prescribing of lipid-lowering drugs: A randomized controlled trial in Swedish primary
care. Journal of Clinical Epidemiology, 48(5), 705-711.

Drexel, Merlo, Basile, Watkins, Whitfield, Katz, Pine & Sullivan (2011). Highly interactive
multi-session programs impact physician behavior on hypertension management: outcomes of a
new CME model. Journal of Clinical Hypertension, 13(7): 538

El-Mallakh, P., & Findlay, J. (2015). Strategies to improve medication adherence in patients with
schizophrenia: the role of support services. Neuropsychiatric disease and treatment, 11, 1077–
1090. doi:10.2147/NDT.S56107
ESH (n.d.) Eastern State Hospital Managed by UK HealthCare. Retrieved from
https://ukhealthcare.uky.edu/eastern-state-hospital
23

THE EFFECT OF LAI PSCHOTROPIC MEDICATION
Freemantle, N., Nazareth, I., Eccles, M., Wood, J., & Haines, A. (2003). A randomized
controlled trial of the effect of educational outreach by community pharmacists on prescribing in
UK general practice. The British Journal of General Practice: The Journal of the Royal College
of General Practitioners, 52(477), 290-295.
Fretheim, A., Oxman, A., Havelsrud, K., Treweek, S., Kristoffersen, D., & Bjorndal, A. (2006).
Rational prescribing in primary care (RaPP): A cluster randomized trial of a tailored
intervention. Plos Medicine, 3(6), 783-791.
Green M, Yan T, Chang E, Harty A, Touya M, Broder MS (2018). Medication adherence and
discontinuation of long acting injectable versus oral antispychotics in patients with schizophrenia
or bipolar disorder. J Med Econ. 21(2), 127-134.
Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al.
(2004). Effectiveness and efficiency of guideline dissemination and implementation
strategies. Health Technology Assessment 2004;8(6):iii‐iv, 1‐72.
Grome, L. J., Banuelos, R. C., Lopez, M. A., Nicome, R. K., & Leaming-Van Zandt, K. (2018).
Communication Course for Pediatric Providers Improves Self-efficacy. Plastic and
Reconstructive Surgery - Global Open, 6(10), E1964.
Gur, Weizman, Stubbs, Matalon, Meyerovitch, Hermesh, & Krivoy. (2018). Mortality, morbidity
and medical resources utilization of patients with schizophrenia: A case-control communitybased study. Psychiatry Research, 260, 177-181.

24

THE EFFECT OF LAI PSCHOTROPIC MEDICATION
Guzman, F. (2018). Long-acting injectable antipsychotics: a summary for prescribers.
Psychopharmacology Institute. Retreived from https://psychopharmacologyinstitute.com/
antipsychotics/long-acting-injectable-antipsychotics-a-practical-guide-for-prescribers/

Higashi, K., Medic, G., Littlewood, K. J., Diez, T., Granström, O., & De Hert, M. (2013).
Medication adherence in schizophrenia: factors influencing adherence and consequences of
nonadherence, a systematic literature review. Therapeutic advances in
psychopharmacology, 3(4), 200-18.
Kaminski, J. (Spring 2011). Diffusion of Innovation Theory Canadian Journal of Nursing
Informatics, 6(2). Theory in Nursing Informatics Column. http://cjni.net/journal/?p=1444
Kaplan, G., Casoy, J., & Zummo, J. (2013). Impact of long-acting injectable antipsychotics on
medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient
preference and adherence, 7, 1171-80. doi:10.2147/PPA.S53795
Mooney, Hamper, Willis, Farinha, & Ricchetti. (2018). Evaluating patient satisfaction with
pharmacist-administered long-acting injectable antipsychotics in the community
pharmacy. Journal of the American Pharmacists Association, 58(4), S24-S29.e2.
O'Brien, M., Rogers, S., Jamtvedt, G., Oxman, A., Odgaardjensen, J., Kristoffersen, D., . . .
Harvey, E. (2007). Educational outreach visits: Effects on professional practice and health care
outcomes. Cochrane Effective Practice and Organisation of Care Group, (4).
Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A.
(2008). Cost-effectiveness analysis of switching antipsychotic medication to long-acting

25

THE EFFECT OF LAI PSCHOTROPIC MEDICATION
injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the eSTAR database in Spain. Appl Health Econ Health Policy. 6(1):41–53.

Park, S. C., Choi, M. Y., Choi, J., Park, E., Tchoe, H. J., Suh, J. K., Kim, Y. H., Won, S. H.,
Chung, Y. C., Bae, K. Y., Lee, S. K., Park, C. M., … Lee, S. H. (2018). Comparative Efficacy
and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the
Treatment of Schizophrenia: A Systematic Review and Meta-analysis. Clinical
psychopharmacology and neuroscience : the official scientific journal of the Korean College of
Neuropsychopharmacology, 16(4), 361-375.
Peng, X., Ascher-Svanum, H., Faries, D., Conley, R. R., & Schuh, K. J. (2011). Decline in
hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of
schizophrenia. ClinicoEconomics and outcomes research: CEOR, 3, 9-14.
Psychopharmacology Institute (2018). About psychopharmacology institute.
Psychopharmacology Institute. Retrieved from: https://psychopharmacologyinstitute.com/aboutproject/
Sadock, B. J., Sadock, V. A., & Ruiz, P. (2015). Kaplan & Sadock's synopsis of psychiatry:
Behavioral sciences/clinical psychiatry (Eleventh edition.). Philadelphia: Wolters Kluwer.
Smart Retaling Rx (2018). Does your pharmacy offer antipsychotic injections? Health Mart
Pharmacy. Retrieved from https://join.healthmart.com/business-and-operations/does-yourpharmacy-offer-antipsychotic-injections/

26

THE EFFECT OF LAI PSCHOTROPIC MEDICATION
Soumerai, S., Salem-Schatz, S., & Avorn, J. (1993). A Controlled Trial of Educational Outreach
to Improve Blood Transfusion Practice. 270(8), 961-966.
Sullivan, T. (2018). ACCME annual report data 2014. Policy and Medicine A Rockpointe
Publication. Retrieved from https://www.policymed.com/2015/07/accme-annual-report-data2014.html
Turrina, C., Valsecchi, P., Mosca, A., Parrinello, G., Tabaglio, E., Brignoli, O., & Sacchetti, E.
(2008). Immediate and 8-month impact of a medical educational course for general practitioners
on knowledge about schizophrenia and its treatment: Results of a 3-phase study from Brescia,
Italy. Primary Care Companion to the Journal of Clinical Psychiatry, 10(6), 457-461.

Witt, K., Knudsen, E., Ditlevsen, S., & Hollnagel, H. (2004). Academic detailing has no effect
on prescribing of asthma medication in Danish general practice: A 3-year randomized controlled
trial with 12-monthly follow-ups. Family Practice, 21(3), 248-253.
World Health Organization (2018). Schizophrenia. Retrieved from https://www.who.int/newsroom/fact-sheets/detail/schizophrenia
World Health Organization (2019). Schizophrenia. Retrieved from https://www.who.int/newsroom/fact-sheets/detail/schizophrenia
Zhang, X., Yu, P., Yan, J., & Ton A M Spil, I. (2015). Using diffusion of innovation theory to
understand the factors impacting patient acceptance and use of consumer e-health innovations: A
case study in a primary care clinic Healthcare needs and demand. BMC Health Services
Research,15(1), 71.

27

THE EFFECT OF LAI PSCHOTROPIC MEDICATION
Zhornitsky, S., & Stip, E. (2012). Oral versus Long-Acting Injectable Antipsychotics in the
Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A
Systematic Review. Schizophrenia Research and Treatment, 2012(2012), 407171.

28

